FTI-2153
| 中文名稱 | FTI-2153 |
|---|---|
| 中文同義詞 | 化合物 T15353;化合物 FTI-2153 |
| 英文名稱 | FTI-2153 |
| 英文同義詞 | FTI-2153;L-Methionine, N-[[5-[[(1H-imidazol-5-ylmethyl)amino]methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester;L-Methionine,N-[[5-[[(1H-imidazol-4-ylmethyl)amino]methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester;FTI2153,FTI 2153 |
| CAS號(hào) | 344900-92-1 |
| 分子式 | C25H30N4O3S |
| 分子量 | 466.6 |
| EINECS號(hào) | |
| 相關(guān)類別 | |
| Mol文件 | 344900-92-1.mol |
| 結(jié)構(gòu)式 |  |
FTI-2153 性質(zhì)
| 沸點(diǎn) | 700.1±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.210±0.06 g/cm3(Predicted) |
| 儲(chǔ)存條件 | Store at -20°C |
| 溶解度 | 二甲基亞砜：100 mg/mL（214.32 mM） |
| 酸度系數(shù)(pKa) | 13.00±0.46(Predicted) |
| 形態(tài) | 固體 |
| 顏色 | 米白色至淺黃色 |
FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status in two human lung cancer cell lines.
FTI-2153 increases the percentage of prometaphase cells with ring-like DNA morphology in transformed and non-transformed cells.
FTI-2153 (15 μM) inhibits T-24 and Calu-1 cell growth by 38 and 36%, respectively. NIH3T3, HFF and HT-1080 are less sensitive and are inhibited by only 8, 8 and 13%, respectively. A-549 and OVCAR3 cell growth is inhibited by 25 and 22%, respectively. Thus, even though T-24 and Calu-1 cells are equisensitive to FTI-2153 cell growth inhibition, FTI-2153 inhibits bipolar spindle formation only in Calu-1 cells. HFF and NIH3T3 cells are both resistant to FTI2153 growth inhibition, yet only NIH3T3 cells are resistant to FTI-2153 inhibition of bipolar spindle formation.
Cell Viability Assay
| Cell Line: | NIH3T3, HFF, HT1080, T-24, OVCAR3, A-549 and Calu-1 CELLS. |
| Concentration: | 48 h. |
| Incubation Time: | 15 μM. |
| Result: |
When A-549 cells were treated with FTI-2153 (15 μM for 48 h), the proportion of cells at prometaphase increased relative to the other phases of mitosis.
FTI-2153 accumulated cells at prometaphase with a rosette-like morphology where chromosomes form a ring surrounding a monoaster of microtubules. In all cells, except for T-24 and NIH3T3, FTI-2153 treatment increased the proportion of mitotic cells in prometaphase and decreased the percentage of cells in telophase/cytokinesis. In HT1080 cells, the percentage of cells in prometaphase and telophase/ cytokinesis were 5 and 85% in control cells and 55 and 35% in Treated cells, respectively. Similarly results were also found in HFF cells. Calu-1 and A-549 cells, as described previously, had similarly large changes, whereas OVCAR3 had smaller changes. In contrast, FTI-2153 did not significantly affect the distribution of the different phases of mitosis in T-24 and NIH3T3 cells. |
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-123242 | FTI-2153 | 344900-92-1 | 1 mg | 2045元 |
| 2025/05/22 | HY-123242 | FTI-2153 FTI-2153 | 344900-92-1 | 5mg | 4500元 |